# A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue Testing

> **NCT06129084** · — · ACTIVE_NOT_RECRUITING · sponsor: **Bernie Eigl** · enrollment: 260 (actual)

## Conditions studied

- Metastatic Bladder Cancer
- Metastatic Urothelial Carcinoma

## Interventions

- **GENETIC:** FGFR Testing

## Key facts

- **NCT ID:** NCT06129084
- **Lead sponsor:** Bernie Eigl
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-01-11
- **Primary completion:** 2025-09-15
- **Final completion:** 2026-12-31
- **Target enrollment:** 260 (ACTUAL)
- **Last updated:** 2025-12-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06129084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06129084, "A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue Testing". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06129084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*